Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

107.83 +2.44 (+2.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Why Incyte (INCY) Stock Is Up Today
What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.8% in the morning session after several analyst firms raised the... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Credit Cards Stocks
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
Via The Motley Fool
Topics Regulatory Compliance
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗
Via Chartmill
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
Incyte (NASDAQ:INCY) Beats Q1 Estimates and Unveils Robust Pipeline Catalysts ↗
Via Chartmill
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
3 Profitable Stocks for Long-Term Investors
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia... 
Via StockStory
News headline image
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗
Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody... 
Via MarketBeat
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build ↗
Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,... 
Via MarketBeat
News headline image
2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
News headline image
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions
Incyte’s first quarter results were shaped by strong demand across its commercial portfolio, with growth supported by both new and existing products in hemat... 
Via StockStory
Topics Earnings
News headline image
INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 20.9% year on year to $1.27 bi... 
Via StockStory
News headline image
Incyte (INCY) Q1 2026 Earnings Call Transcript ↗
Incyte (INCY) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Incyte (INCY) Q2 2025 Earnings Transcript ↗
Incyte (INCY) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 20.9% year on... 
Via StockStory
News headline image
Incyte Earnings: What To Look For From INCY
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for. Incyte beat analy... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte (INCY) Q4 2024 Earnings Transcript ↗
Incyte (INCY) Q4 2024 Earnings Transcript 
Via The Motley Fool
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup ↗
Incyte Corp (INCY) shows strong earnings growth and a positive technical setup, suggesting a potential breakout for momentum investors. 
Via Chartmill
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
2 Value Stocks to Consider Right Now and 1 We Ignore
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% inc... 
Via StockStory
Topics Stocks
News headline image
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal... 
Via Stocktwits
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 S&P 500 Stocks to Target This Week
The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to strong fundamentals and sustained competitive... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.